



Vaginal self-versus clinician sampling on cervical cancer screening: an accuracy and acceptability systematic review and meta-analysis

Mafalda Paula-Pinto,¹ Marta Amaral,² Leonor Norton,¹ Francisca Vilas-Boas,² Inês Santos-Silva³

RESUMO

Introduction: Self-sampling strategies have shown promising efficacy in detecting disease, but it is still unclear whether these strategies can be implemented independently of a clinical setting in a manner acceptable to women.

Objectives: This review aimed to evaluate the accuracy – non-inferiority – of human papillomavirus (HPV) detection rates between clinician-collected samples and self-sampling, and secondarily to assess the acceptability of self-sampling for cervical cancer screening.

Methods: A systematic search was performed mainly from electronic databases (MEDLINE, CENTRAL, and Scopus). Studies that compared both screening methods of and that contained data on their accuracy and acceptability were included. Two independent researchers performed study selection and data extraction. An assessment of the risk of bias was done using the QUADAS2 and Cochrane Risk of Bias Tool. The pooled sensitivity and specificity of tests were estimated and SROC curves were built. A subgroup and sensitivity analysis were performed. RevMan5.4. and Meta-DiSc® 1.4.7. were used.

Results: Sixty-seven articles were included, 47 regarding accuracy and 36 regarding acceptability, with a total sample of 18,615 women aged between 15 and 80. This study showed that self-sampling, as a screening test, has a sensitivity of 87.4% and specificity of 91.2% to detect HPV. From subgroup analysis, no significant differences were detected regarding the type of test, transport-device, or HPV prevalence. Regarding acceptability, women consider self-sampling to be easy, comfortable, and non-embarrassing. 62.8% preferred collection by self-sampling.

Conclusion: This way of self-sampling HPV screening proved not inferior to clinician-sampling and has good acceptability among women, making it a possible alternative or complement to conventional screening. Nevertheless, there is still low evidence regarding its feasibility and applicability, therefore the next step should focus on evaluating the cost-effectiveness of this type of screening at a national and international level.

Keywords: Human papillomavirus; Cervical cancer; Self-collection; Screening; Diagnostic testing; Acceptability.

INTRODUCTION

Cervical cancer is the fourth most common cancer worldwide and is more expressive among middle-aged women and in underdeveloped and developing countries.¹ Its screening has proven to have a major impact on prognosis since it provides detection at the early stages of the disease.²

Nowadays, in countries with well-organized screening and low rates of cervical cancer, its incidence is in-

creasing, which can be explained by several factors. One reason is that exposure to HPV has increased over time.³ Other reasons relate to the fact that certain types of sexual orientation, cultural beliefs, and socioeconomic

1. Médica Interna de Medicina Geral e Familiar. USF Ramalde, ULS de Santo António. Porto, Portugal.

2. Especialista de Medicina Geral e Familiar. USF Ramalde, ULS de Santo António. Porto, Portugal.

3. Especialista de Medicina Geral e Familiar. USF Ars Médica, ULS de Loures/Odivelas. Lisboa, Portugal.



status seem to be responsible for the lack of screening, even in well-developed countries.^{1,4} Therefore, the development of strategies to improve cervical cancer screening must be a priority. Regarding HPV vaccination, authors consider that it is unlikely to lead to an increased incidence of cervical cancer because of diminished screening, despite the sense of protection from the vaccine in vaccinated women.⁵ However, the impact of risk reduction will reflect on the cost-effectiveness of screening, whether done by clinician or self-sampling.

HPV screening not only has shown to be more effective as compared to cytology alone, but it also provides the possibility to be self-collected.⁶ In fact, this type of HPV screening can engage many women participating in screening programs, eliminating cultural barriers or the embarrassment that some women complain about. It will also reduce health costs and the professional's workload, along with more acceptance and population coverage.⁷ This type of sample can also play an interesting role in some contexts of reduced access to health care and scarcity of human resources, such as the one experienced during the COVID-19 pandemic, in which there was a significant delay in cervical cancer screening.⁸

There are few studies evaluating the accuracy of self-sampling, leaving doubts about its effectiveness, especially when influenced by factors such as the type of HPV assays, self-sampling device, and means of conservation. Furthermore, there is little evidence regarding the acceptability of self-sampling by women.⁹ The purpose of this systematic review and meta-analysis was to determine the accuracy (non-inferiority) of HPV detection in self-samples compared to those collected by a health professional and assess women's acceptability regarding this alternative for cervical cancer screening.

METHODS

A systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.⁹ It was registered in the PROSPERO database (Prospero 2021 CRD42021251996).

The Population, Intervention, Comparator, and Outcome (PICO) components used to define eligibility criteria for this article were: population, sexually active

women eligible for cervical cancer screening according to international cancer screening guidelines. Studies including individuals with a prior history of cervical cancer were excluded. For intervention, Index test – Cervical/Vaginal screening with self-sampling for HPV DNA detection test – including all different instruments of collection, transportation devices, or analysis methods. Reference standard: Cervical/Vaginal screening collected by clinicians, of any specialty, for HPV DNA detection test. Excluding other types of screening methods that involve healthcare providers (e.g. VIA, colposcopy, or biopsy).

The main outcomes were measuring accuracy in HPV detection (rates) between clinician-collected samples and self-sampling and if the accuracy in HPV detection rates between clinician-collected samples and self-sampling was similar for all HPV strains, high-risk strains, and low-risk strains. For additional outcomes, we defined the measure of acceptability of self-sampling by women, defined as women's capacity to perform and accept the test.

Search strategy

Articles published in the electronic databases MEDLINE, CENTRAL, and Scopus were searched, along with unpublished studies, ongoing clinical trials (ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform), conference abstracts of the International Papillomavirus Society, and key journals. A free search on the Google Scholar search engine was also carried out. This research was conducted on March 4, 2022, and performed without any restrictions on dates, language, publication type, or region.

The following query was used: (HPV [title/abstract] OR human papillomavirus [Title/Abstract] OR (cancer [Title/Abstract]) AND (cervic* [Title/Abstract]) OR alphapapillomavirus [MeSH Terms] OR papillomavirus infections [MeSH Terms] OR papillomavirus infection [MeSH Terms] OR uterine cervical neoplasms [MeSH Terms]) AND (vaginal sample* [Title/Abstract] OR screening test* [Title/Abstract] OR test* [Title/Abstract] OR early detection of cancer [MeSH Terms] OR papanicolaou smear [MeSH Terms] OR Human Papillomavirus DNA Tests [MeSH Terms]) AND (self-collect* [Title/Abstract] OR self-sample* [Title/Abstract] OR self [Title/Abstract]).



Eligibility criteria, articles selection and quality assessment

Initially, an eligibility screening of the studies was carried out based on their titles and abstracts and regarding our inclusion criteria. A second screening was performed based on the full text. Eligibility criteria included studies that compared both methods of screening (self and physician sampling) using only vaginal and cervical biological samples and studies that contained data on its accuracy. We excluded studies published in non-Roman characters, studies only comparing self-samples themselves or using other types of samples (tampons, urine, non-vaginal/cervical). Regarding acceptability, women would have to undergo both tests (self and clinician) and answer a questionnaire. This selection process was conducted independently by three different authors. Researchers were blinded to each other's decisions. Disagreements were resolved by consensus or, when not possible, by a fourth researcher.

An assessment of the risk of bias was done using the Diagnostic Precision Study Quality Assessment Tool (QUADAS-2 tool). The four domains assessed were patient selection, index test, reference standard, and flow and timing. Each domain was evaluated by the following classifications according to judgment – low risk, high risk, and unclear risk. Two reviewers performed the quality assessment independently. The assessment was performed using the Review Manager Software version 5.4 (RevMan, v. 5.4). For acceptability analysis, the risk of bias was assessed using the Cochrane Risk of Bias Tool (RoB2) and for non-randomized studies, the Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool was used. Using the Rayyan platform, any disagreement was resolved by consensus or, when not possible to solve, by a third researcher.

Data extraction

Two authors, independently, extracted data using a data extraction form. Information was collected on general study details, HPV prevalence, tests' characteristics, and diagnostic test results (true positive, TP; true negative, TN; false positive, FP; false negative, FN; sensitivity, SEN; specificity, SPE; and accuracy) or data that allowed their calculation, acceptability of self-sampling and preference of collection method, women follow up

after screening and risk of bias information. Data was recorded using an Excel spreadsheet.

Statistical analysis

A meta-analysis was performed according to the technique and type of sample from each study, by subgroups. The pooled SEN and SPE of tests were estimated based on the TP, TN, FP, and FN rates extracted. SROC curves based on TP e FP rates were also built whenever possible. RevMan 5.4. and Meta-DiSc® 1.4.7. were used for data analysis.

As a high heterogeneity was expected due to the variation in sensitivity and threshold effect, a subgroup and sensitivity analysis was also performed. To assess acceptability a descriptive analysis was carried out with data based on responses given to questionnaires submitted after performing a self-sampling procedure. Heterogeneity tests were conducted (Q-test and I2 statistic), with inconsistency values I2 greater than 50% being considered as moderate heterogeneity and I2 greater than 75% defined as high heterogeneity. Outcomes with I2 values greater than 50% were submitted to sensitivity analysis and a random effects model was used.

RESULTS

Selection of studies

The literature search process is presented in Figure 1. A total of 2,553 articles were obtained. Following the removal of duplicates, reviews, meta-analysis, and systematic reviews, 1,644 articles did not meet our inclusion criteria, resulting in a total of 180 articles. One hundred and thirteen articles were excluded after full text analysis resulting in a total of 67 articles included, 47 regarding accuracy and 36 regarding acceptability.¹¹⁻⁷⁷

Characteristics of included studies and participants

All 47 articles concerning accuracy were cross-sectional, with a total sample size of 18,615 women aged between 15 and 80 years and a total of 62 combinations between self and clinician samples. The study setting was divided into four large subgroups, considering some characteristics and prevalence of HPV: healthy women, concomitant HPV or HIV infection, known dysplasia, and medical history of cervical cancer. Concerning the healthy women subgroup, a total of 21 articles were drawn, including 12,876 women and an HPV




Figure 1. PRISMA flow diagram.

prevalence ranging from 3.7-33.9%. For concomitant HPV or HIV infection, known dysplasia, and medical history of cervical cancer the numbers were six, 16, and two articles drawn, including 12,876, 1,875, 3,500, and 346 women and an HPV prevalence ranging from 21.7-84.3%, 30-78.4% and 78-89%, respectively.

HPV infection was assessed by tests targeting DNA except for APTIMA HPV assay, which targeted RNA. Regarding the material, in the self-sampling group, a swab was used in 23 studies, and a brush in 24. For physician-sampling, a swab was used in 10 studies and a brush in 37. Normally, cervical specimens were preserved in




Figure 2. Quality assessment – QUADAS2 – of all included studies in the meta-analysis.

cytology-conserving media. Half of the studies reported that self-sampling tests were carried out at home and the other half in private medical offices, most of them with the help of written instructions. Both tests were made on the same day except for seven studies, with time intervals ranging from one and three weeks.

Regarding acceptability, only two studies were randomized control trials, with a total sample size of 17,706 women aged between 15 and 80 years old. The analysis was done considering three categories of acceptability: easy (20 articles – 6,459 women), convenient (13 articles – 6,192 women), and not embarrassing (15 articles – 6,647 women). The preference analysis included 25 articles (11,594 women) for self-sampling and 11 articles (7,341 women) for clinician sampling. Descriptive details and findings of the studies included in this review are presented in Tables 1 and 2.

Assessment of risk of bias

Figure 2 displays the quality judgments for each QUADAS-2 item in all 47 included studies for accuracy, which quality appeared to be adequate. The quality judgment for acceptability using ROBINS-I also appeared to be adequate.

Diagnostic accuracy

The overall SEN was 0.874 (95%CI, 0.85-0.894), overall SPE was 0.912 (95%CI, 0.888-0.931), diagnostic odds ratio (DOR) was 71.654 (95%CI, 51.149-92.158), positive likelihood ratio (PLR) was 9.915 (95%CI, 7.594-12.236) and negative likelihood ratio (NLR) was 0.138

(95%CI, 0.115-0.162). The SROC curve illustrates the relationship between SEN and SPE. I^2 for SEN was 0.700 (percentile 2.5/97.5, 0.670-0.740), for SPE was 0.810 (percentile 2.5/97.5, 0.780-0.830) and I^2 bivariate was 0.750 (percentile 2.5/97.5, 0.730-0.770), showing substantial heterogeneity among studies.

Subgroup analysis regarding the type of HPV test is shown in Figures 3 and 4. Concerning the analysis of the four large subgroups, the results were: primary screening of generally healthy women SEN 0.828 (95%CI, 0.79-0.86), SPE 0.944 (95%CI, 0.919-0.962), PLR 14.874 (95%CI, 9.21-20.538), NLR 0.182 (95%CI, 0.145-0.22), and DOR 81.579 (95%CI, 43.161-119.996); known HPV or HIV infection SEN 0.930 (95%CI, 0.929-0.931), SPE 0.896 (95%CI 0.895-0.897), PLR 8.982 (95%CI, 8.897-9.067), NLR 0.078 (95%CI, 0.077-0.079), and DOR 115.168 (95%CI, 113.456-116.881); known dysplasia SEN 0.898 (95%CI, 0.868-0.921), SPE 0.856 (95%CI, 0.812-0.891), PLR 6.227 (95%CI, 4.533-7.921), NLR 0.120 (95%CI, 0.088-0.151), and DOR 52.018 (95%CI, 30.098-73.938) and established cervical cancer SEN 0.927 (95%CI, 0.82-0.973), SPE 0.856 (95%CI, 0.812-0.891), PLR 7.181 (95%CI, 2.929-17.292), NLR 0.083 (95%CI, 0.02-0.147), and DOR 86.135 (95%CI, 7.999-164.272). No difference was found between swab or brush, or between storage type.

Sensitivity analysis

The overall sensitivity ranged from 0.875 (95%CI, 0.852-0.896) and 0.881 (95%CI, 0.859-0.9), and overall specificity ranged from 0.906 (95%CI, 0.884-0.925) and




Figure 3A. Main results (Forests plots).




Figure 3B. Summary receiver operating characteristic plane.

Notes: A = Forests plots and SROC plane obtained for all 62 combinations; B = SROC plane for primary screening of generally healthy women; C = SROC plane for known HPV or HIV infections; D = SCROC plane for known dysplasia; E = SROC plane for known cervical cancer. Label: SROC plane = Summary receiver operating characteristic plane; HPV = Human papillomavirus; HIV = Human immunodeficiency virus.




Figure 4. Forest Plots – sensitivity and specificity by type of PCR-Test.

Label: TP = True positive; FP = False positive; FN = False negative; TN = True negative.

0.915 (95%CI, 0.892-0.933). This outcome did not change by excluding any study.

Analysis of acceptability

The analysis was done regarding three categories of acceptability: easy, convenient, and not embarrassing. About 89.6%, 95.5%, and 89.3% of women considered HPV self-sampling easy, convenient, and not embarrassing, respectively. 62.8% preferred self-sampling and 55.6% clinician-sampling.

DISCUSSION

This study showed that self-sampling, as a screening test, has high SEN (87.4%) and SPE (91.2%) to detect HPV and is not inferior when compared to clinician-collected samples. There was significant heterogeneity of results among studies. Looking closer at the impact of certain variables on the precision of self-sampling, the lack of methodological information made a more detailed analysis impossible. Nevertheless, our findings proved that the outcome was not significantly affected by women's medical background (including previous HPV/HIV infection or lesions in previous cytology), type of sampling, material used, conditions of transportation and storage, or type of test used.

HPV screening for cervical cancer has been widely used in many European and other developed countries as a preferred screening method or as a complement to organized national screening programs.⁷⁸ It has shown to be highly cost-effective, as well as having high sensitivity to detect cervical cancer.⁷⁹ The introduction of HPV self-sampling as part of screening can help reduce costs and physician's workload.⁸⁰ Moreover, it can have a major impact on increasing participation in cervical cancer screening. It



has been shown that women who have never had this type of screening or who did not manage to meet a correct follow-up were twice as likely to participate if using the self-sample test.⁸¹ Our study supports these findings, with a total of 62.8% of women choosing HPV self-sampling over the clinician one. Such outcomes can be explained by a variety of reasons. Not only does it ensure a safer environment, eliminating the discomfort described by some women during gynecological examinations, but it also allows more access to those who live far away from healthcare centers. Furthermore, it seems to be a simple and convenient way of screening, guaranteeing good acceptability among them. 55.6% of women favor collection by a health professional due to the lack of confidence in their ability to perform it. This demonstrates the need to invest in educational programs that reinforce the reliability of this method, otherwise, large-scale implementation will not be cost-effective.

Beyond acceptability itself, the rate of adhesion can be influenced by other factors. Although few studies are addressing these issues, age does not seem to be an influencing factor. Concerning the context in which these tests are carried out, there is discrepant data. Nonetheless, women in rural areas seem to participate less when compared to urban areas, which could be attributed to the lack of adequate logistics and resources.⁸² If this proves to be the case, it is crucial to investigate further reasons for these discrepancies, since rural areas could benefit to a greater extent from the implementation of self-collection HPV tests.

This meta-analysis did not include studies that used samples obtained by urine or tampons since there is not enough evidence to validate their diagnostic accuracy.⁸⁰ The quality of the instructions for the collection kits was not evaluated. Therefore, new studies must be carried out in this area to acknowledge if they are easily understood by women so that campaigns can be developed to promote self-sampling. Some authors have proved that sending the kit home has a higher participation rate than inviting women to sample with a professional.⁸¹ Other tactics, such as providing women with kits during their routine doctor appointments or making it possible to request online, may be an alternative to improve participation.⁸³

Regarding adverse effects or social harms, none have been identified specifically for self-sampling, since an-

xiety, distress, stigma, need for disclosure, and guilt for the cause after a positive HPV result commonly accompany an abnormal pap smear or clinical sampling for HPV, because of its sexually transmitted nature.⁸⁴⁻⁸⁵ Some of the disadvantages reported, were pain and physical discomfort, anxiety, insecurity concerning obtaining sufficient material for testing, and embarrassment in touching themselves.⁷⁹ Nonetheless, those events were not assessed in the studies included in this systematic review and meta-analysis.

Despite all the advantages mentioned above, HPV self-collection still does not allow the performance of reflex cytology, which implies notifying women to repeat the test with a professional when there is a positive result.⁹ This fact not only increases associated costs but also reintroduces the discomfort that was supposed to be eliminated, questioning the applicability of this type of screening.⁸⁶ However, some promising studies suggest the use of DNA gene hypermethylation tests as an oncogenic marker, providing important additional information that will allow us to overcome this limitation in the medium term.⁸⁷ Additionally, in Next Generation Sequencing, a few human microRNAs and proteins are emerging as biomarkers that have shown promising results.^{9,88}

Since less than 10% of acute HPV infections progress to high-grade lesions or invasive cancer, overdiagnosis and overtreatment of transient infections are some of the main concerns for this type of screening.⁸⁹

Self-sampling may have limited impact in particular contexts, mostly in developing countries, given the associated costs and innovation technologies underlying the implementation of HPV detection strategies. Although the recent context of the COVID-19 pandemic enabled the development of a large number of infrastructures, the acquisition of advanced laboratory material and human resources all over the world, resources that could now be channeled to detect cervical cancer, due to HPV testing reagents, device and assay combinations, laboratory protocols and automated testing machines are the same used for testing COVID-19.⁸ Another advantage of self-sampling devices is that they do not need a cold chain and are stable after collection, this way allowing to minimize costs.⁹⁰

From our standpoint, HPV self-sampling is an important milestone in the history of cervicovaginal scree-



ning. Evidence emerging in the last few years has managed to support the idea that this method has the potential to improve adherence to screening and to promote earlier detection of HPV worldwide. Nevertheless, the assessment of the cost-effectiveness of moving from clinician-collected to self-collected HPV testing in cervical screening is complex and highly individualized. Numerous factors need consideration, such as the setting, vaccination coverage, and herd immunity, as well as the selected triage strategy.

This study reinforced this concept by conducting a simultaneous analysis of the effectiveness and acceptability of self-sampling methods and including a total of 18,615 women allowing conclusions to be drawn with confidence. However, there are no studies that properly assess the best implementation strategies, and cost-effectiveness and objectively define follow-up plans after a positive result, making further investigation necessary in this regard.

CONCLUSION

This systematic review with meta-analysis proved that self-sampling HPV screening is not inferior to clinician sampling and has good acceptability among women, making it a possible alternative or complement to conventional screening. This is a major step towards including more women in screening and ensuring earlier detection of HPV infections. The World Health Organization strongly recommended the use of self-sampling for the control of cervical cancer by 2030 and reduce cervical cancer by screening and treating identified cervical lesions.⁹¹ Nevertheless, there is still low evidence regarding the cost-effectiveness of this type of screening at a national level – some issues demanding attention as: how to and whom to offer self-sampling screening, triage, and follow-up of HPV positive cases and infrastructures and personal resources needed – should be investigated shortly, as well as investing in increasing awareness for cervical cancer and women's acceptability about self-sampling by conducting studies that corroborate its reliability.

REFERENCES

- Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. *Ann Oncol*. 2011;22(12):2675-86.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86.
- Pan S, Wei W, Du X, Li Z, Tuo J, Zhang M, et al. Factors associated with persistence and clearance of HPV16/18 among rural Chinese women: a cohort study in Wufeng, Hubei province. *Women Health*. 2022;62(4):276-86.
- Greibe Andersen J, Shrestha AD, Gyawali B, Neupane D, Kallestrup P. Barriers and facilitators to cervical cancer screening uptake among women in Nepal: a qualitative study. *Women Health*. 2020;60(9):963-74.
- Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, et al. Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? *Cancer Epidemiol Biomarkers Prev*. 2015;24(5):773-82.
- Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. *Cochrane Database Syst Rev*. 2017;8(8):CD008587.
- Bertucci M, Bonnet E, Satger L, Kreiche A, Chappert JL, Loy-Morel S, et al. Acceptability of vaginal self-sampling with high-risk human papillomavirus testing for cervical cancer screening: a French questionnaire-based study. *Women Health*. 2021;61(1):83-94.
- WHO Department for NCDs. Rapid assessment of service delivery for noncommunicable diseases (NCDs) during the COVID-19 pandemic: final results [homepage]. Geneva: WHO; 2020. Available from: <https://www.who.int/publications/m/item/rapid-assessment-of-service-delivery-for-ncds-during-the-covid-19-pandemic>
- Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB. Cervical cancer screening postpandemic: self-sampling opportunities to accelerate the elimination of cervical cancer. *Int J Womens Health*. 2021;13:841-59.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
- Adedimeji A, Ajeh R, Dzudie A, Kendowo E, Fuhngwa N, Nsame D, et al. Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon. *J Clin Virol*. 2020;128:104445.
- Saville M, Hawkes D, Keung M, Ip E, Silvers J, Sultana F, et al. Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study. *J Clin Virol*. 2020;127:104375.
- Kuriakose S, Sabeena S, Binesh D, Abdulmajeed J, Ravishankar N, Ramachandran A, et al. Diagnostic accuracy of self-collected vaginal samples for HPV DNA detection in women from South India. *Int J Gynaecol Obstet*. 2020;149(2):219-24.
- Satake H, Inaba N, Kanno K, Mihara M, Takagi Y, Kondo N, et al. Comparison study of self-sampled and physician-sampled specimens for high-risk human papillomavirus test and cytology. *Acta Cytol*. 2020;64(5):433-41.
- Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignon-Viguier N, et al. Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study. *Gynecol Oncol*. 2014;134(2):302-8.
- Catarino R, Vassilakos P, Bilancioni A, Bougel S, Boukrid M, Meyer-Ham-



- me U, et al. Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay. *PLoS One*. 2017;12(7):e0181905.
17. Guan Y, Gravitt PE, Howard R, Eby YJ, Wang S, Li B, et al. Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. *J Virol Methods*. 2013;189(1):167-71.
 18. Phoolcharoen N, Kantathavorn N, Krisorakun W, Sricharunrat T, Tee-rayathanakul N, Taepisitpong C, et al. Agreement of self- and physician-collected samples for detection of high-risk human papillomavirus infections in women attending a colposcopy clinic in Thailand. *BMC Res Notes*. 2018;11(1):136.
 19. Dijkstra MG, Heideman DA, van Kemenade FJ, Hogewoning KJ, Hesselink AT, Verkuijten MC, et al. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. *J Clin Virol*. 2012;54(2):147-51.
 20. McLarty JW, Williams DL, Loyd S, Hagensee ME. Cervical human papillomavirus testing with two home self-collection methods compared with a standard clinically collected sampling method. *Sex Transm Dis*. 2019;46(10):670-5.
 21. Chang CC, Tseng CJ, Liu WW, Jain S, Horng SG, Soong YK, et al. Clinical evaluation of a new model of self-obtained method for the assessment of genital human papilloma virus infection in an underserved population. *Chang Gung Med J*. 2002;25(10):664-71.
 22. Safaiean M, Kiddugavu M, Gravitt PE, Ssekasanvu J, Murokora D, Sklar M, et al. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. *Sex Transm Dis*. 2007;34(7):429-36.
 23. Latiff LA, Ibrahim Z, Pei CP, Rahman SA, Akhtari-Zavare M. Comparative assessment of a self-sampling device and gynecologist sampling for cytology and HPV DNA detection in a rural and low resource setting: Malaysian experience. *Asian Pac J Cancer Prev*. 2015;16(18):8495-501.
 24. Gage JC, Partridge EE, Rausa A, Gravitt PE, Wacholder S, Schiffman M, et al. Comparative performance of human papillomavirus DNA testing using novel sample collection methods. *J Clin Microbiol*. 2011;49(12):4185-9.
 25. Bergengren L, Kaliff M, Larsson GL, Karlsson MG, Helenius G. Comparison between professional sampling and self-sampling for HPV-based cervical cancer screening among postmenopausal women. *Int J Gynaecol Obstet*. 2018;142(3):359-64.
 26. Nutthachote P, Oranratanaphan S, Termrungruanglert W, Triratanachatt S, Chaiwongkot A, Baedyananda F, et al. Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening. *Taiwan J Obstet Gynecol*. 2019;58(4):477-81.
 27. Lack N, West B, Jeffries D, Ekpo G, Morison L, Soutter WP, et al. Comparison of non-invasive sampling methods for detection of HPV in rural African women. *Sex Transm Infect*. 2005;81(3):239-41.
 28. Castle PE, Aftab A, Saint-Jean G, Mendez L. Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. *J Clin Microbiol*. 2006;44(6):2158-9.
 29. Chernesky M, Jang D, Gilchrist J, Elit L, Lytwyn A, Smieja M, et al. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. *Sex Transm Dis*. 2014;41(6):365-8.
 30. Daponte A, Pournaras S, Mademtzis I, Hadjichristodoulou C, Kostopoulou E, Maniatis AN, et al. Evaluation of HPV 16 PCR detection in self-collected compared with clinician-collected samples in women referred for colposcopy. *Gynecol Oncol*. 2006;103(2):463-6.
 31. Qin Y, Zhang H, Marlowe N, Fei M, Yu J, Lei X, et al. Evaluation of human papillomavirus detection by Abbott m2000 system on samples collected by FTA Elute™ Card in a Chinese HIV-1 positive population. *J Clin Virol*. 2016;85:80-5.
 32. Chen Q, Du H, Zhang R, Zhao JH, Hu QC, Wang C, et al. Evaluation of novel assays for the detection of human papilloma virus in self-collected samples for cervical cancer screening. *Genet Mol Res*. 2016;15(2).
 33. Toliman PJ, Kaldor JM, Badman SG, Phillips S, Tan G, Brotherton JML, et al. Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting. *Clin Microbiol Infect*. 2019;25(4):496-503.
 34. Wong EL, Chan PK, Chor JS, Cheung AW, Huang F, Wong SY. Evaluation of the impact of human papillomavirus DNA self-sampling on the uptake of cervical cancer screening. *Cancer Nurs*. 2016;39(1):E1-E11.
 35. Bonilla-Osma LJ, Amaya-Guio J, Olaya-García P, Bonilla-Bula L. Evaluation of the usefulness of a device for human papilloma virus DNA collection and preservation in self-collected cervicovaginal samples stored dry in women with cervical dysplasia, Bogotá, Colombia. *Rev Colomb Obstet Ginecol*. 2018;69(3):179-88.
 36. Chen K, Ouyang Y, Hillemanns P, Jentschke M. Excellent analytical and clinical performance of a dry self-sampling device for human papillomavirus detection in an urban Chinese referral population. *J Obstet Gynaecol Res*. 2016;42(12):1839-45.
 37. Esber A, Norris A, Jumbe E, Kandodo J, Nampandeni P, Reese PC, et al. Feasibility, validity and acceptability of self-collected samples for human papillomavirus (HPV) testing in rural Malawi. *Malawi Med J*. 2018;30(2):61-6.
 38. Campos KL, Machado AP, Almeida FG, Bonin CM, Prata TT, Almeida LZ, et al. Good agreements between self and clinician-collected specimens for the detection of human papillomavirus in Brazilian patients. *Mem Inst Oswaldo Cruz*. 2014;109(3):352-5.
 39. Tranberg M, Jensen JS, Bech BH, Blaakær J, Svanholm H, Andersen B. Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test. *BMC Infect Dis*. 2018;18(1):348.
 40. Ketelaars PJ, Bosgraaf RP, Siebers AG, Massuger LF, van der Linden JC, Wauters CA, et al. High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study. *Prev Med*. 2017;101:96-101.
 41. Castle PE, Gage JC, Partridge EE, Rausa A, Gravitt PE, Scarinci IC. Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta. *BMC Infect Dis*. 2013;13:5.
 42. Wang R, Lee K, Gaydos CA, Anderson J, Keller J, Coleman J. Performance and acceptability of self-collected human papillomavirus testing among women living with HIV. *Int J Infect Dis*. 2020;99:452-7.
 43. Iqdbashian S, Boveri S, Radice D, Casadio C, Spolti N, Sandri MT, et al. Performance of self-sampled HPV test in comparison with liquid based cytology. *Eur J Obstet Gynecol Reprod Biol*. 2014;177:72-6.



44. Dannecker C, Siebert U, Thaler CJ, Kiermeir D, Hepp H, Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. *Ann Oncol*. 2004; 15(6):863-9.
45. Holanda F Jr, Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB. Primary screening for cervical cancer through self sampling. *Int J Gynaecol Obstet*. 2006;95(2):179-84.
46. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed – biologic concordance and women's preferences. *Am J Obstet Gynecol*. 2002;186(3):365-73.
47. Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: a methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. *J Clin Virol*. 2018;99-100:22-30.
48. Obiri-Yeboah D, Adu-Sarkodie Y, Djigma F, Hayfron-Benjamin A, Abdul L, Simporé J, et al. Self-collected vaginal sampling for the detection of genital human papillomavirus (HPV) using care HPV among Ghanaian women. *BMC Womens Health*. 2017;17(1):86.
49. Surriabre P, Allende G, Prado M, Cáceres L, Bellot D, Torrico A, et al. Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in Bolivia. *BMC Womens Health*. 2017; 17(1):135.
50. De Alba I, Anton-Culver H, Hubbell FA, Ziogas A, Hess JR, Bracho A, et al. Self-sampling for human papillomavirus in a community setting: feasibility in Hispanic women. *Cancer Epidemiol Biomarkers Prev*. 2008; 17(8):2163-8.
51. Lim LM, Chan MF, Win PP, Shen L, Arunachalam I, Ng SY, et al. Self-sampling HPV DNA test for cervical cancer screening in Singapore: a prospective study. *Ann Acad Med Singap*. 2022;51(11):733-5.
52. Petignat P, Hankins C, Walmsley S, Money D, Provencher D, Pourreaux K, et al. Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. *Clin Infect Dis*. 2005;41(4):527-34.
53. Agorastos T, Dinas K, Lloveras B, Font R, Kornegay JR, Bontis J, et al. Self-sampling versus physician-sampling for human papillomavirus testing. *Int J STD AIDS*. 2005;16(11):727-9.
54. Asciutto KC, Ernstson A, Forslund O, Borgfeldt C. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. *J Clin Virol*. 2018;101:69-73.
55. Jentschke M, Chen K, Arbyn M, Hertel B, Noskovicz M, Soergel P, et al. Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. *J Clin Virol*. 2016;82:46-50.
56. Asciutto KC, Henningson AJ, Borgfeldt H, Darlin L, Borgfeldt C. Vaginal and urine self-sampling compared to cervical sampling for HPV-testing with the Cobas 4800 HPV test. *Anticancer Res*. 2017;37(8):4183-7.
57. Boggan JC, Walmer DK, Henderson G, Chakhtoura N, McCarthy SH, Beauvais HJ, et al. Vaginal self-sampling for human papillomavirus infection as a primary cervical cancer screening tool in a Haitian population. *Sex Transm Dis*. 2015;42(11):655-9.
58. Islam JY, Mutua MM, Kabare E, Manguro G, Hudgens MG, Poole C, et al. High-risk human papillomavirus messenger RNA testing in wet and dry self-collected specimens for high-grade cervical lesion detection in Mombasa, Kenya. *Sex Transm Dis*. 2020;47(7):464-72.
59. Karwalajtys T, Howard M, Sellors JW, Kaczorowski J. Vaginal self sampling versus physician cervical sampling for HPV among younger and older women. *Sex Transm Infect*. 2006;82(4):337-9.
60. Rosenbaum AJ, Gage JC, Alfaro KM, Ditzian LR, Maza M, Scarinci IC, et al. Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. *Int J Gynaecol Obstet*. 2014;126(2):156-60.
61. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Austin J, et al. Acceptability of unsupervised HPV self-sampling using written instructions. *J Med Screen*. 2006;13(4):208-13.
62. El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb W, Hemmings R, et al. Validation of a new HPV self-sampling device for cervical cancer screening: the Cervical and Self-Sample In Screening (CASSIS) study. *Gynecol Oncol*. 2018;149(3):491-7.
63. Oranratanaphan S, Termrungruanglert W, Khemapech N. Acceptability of self-sampling HPV testing among Thai women for cervical cancer screening. *Asian Pac J Cancer Prev*. 2014;15(17):7437-41.
64. Bakiewicz A, Rasch V, Mwaiselage J, Linde DS. "The best thing is that you are doing it for yourself" – Perspectives on acceptability and feasibility of HPV self-sampling among cervical cancer screening clients in Tanzania: a qualitative pilot study. *BMC Womens Health*. 2020;20(1):65.
65. Guan Y, Castle PE, Wang S, Li B, Feng C, Ci P, et al. A cross-sectional study on the acceptability of self-collection for HPV testing among women in rural China. *Sex Transm Infect*. 2012;88(7):490-4.
66. Khoo SP, Lim WT, Rajasuriar R, Nasir NH, Gravitt P, Woo YL. The acceptability and preference of vaginal self-sampling for human papillomavirus (HPV) testing among a multi-ethnic Asian female population. *Cancer Prev Res*. 2021;14(1):105-12.
67. Taku O, Meiring TL, Gustavsson I, Phohlo K, Garcia-Jardon M, Mbulawa ZZ, et al. Acceptability of self-collection for human papillomavirus detection in the Eastern Cape, South Africa. *PLoS One*. 2020;15(11): e0241781.
68. Anhang R, Nelson JA, Telerant R, Chiasson MA, Wright TC Jr. Acceptability of self-collection of specimens for HPV DNA testing in an urban population. *J Womens Health*. 2005;14(8):721-8.
69. Phoolcharoen N, Kantathavorn N, Krisorakun W, Taepisitpong C, Krongthong W, Saeloo S. Acceptability of self-sample human papillomavirus testing among Thai women visiting a colposcopy clinic. *J Community Health*. 2018;43(3):611-5.
70. Kohler RE, Elliott T, Monare B, Moshashane N, Ramontshonyana K, Chatterjee P, et al. HPV self-sampling acceptability and preferences among women living with HIV in Botswana. *Int J Gynaecol Obstet*. 2019;147(3):332-8.
71. Berner A, Hassel SB, Tebeu PM, Untiet S, Kengne-Fosso G, Navarra I, et al. Human papillomavirus self-sampling in Cameroon: women's uncertainties over the reliability of the method are barriers to acceptance. *J Low Genit Tract Dis*. 2013;17(3):235-41.
72. Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. *J Med Screen*. 2007;14(1): 34-42.
73. Manguro GO, Masese LN, Mandaliya K, Graham SM, McClelland RS, Smith JS. Preference of specimen collection methods for human pa-



- papillomavirus detection for cervical cancer screening: a cross-sectional study of high-risk women in Mombasa, Kenya. *Reprod Health*. 2018; 15(1):206.
74. Igdbashian S, Boveri S, Spolti N, Radice D, Sandri MT, Sideri M. Self-collected human papillomavirus testing acceptability: comparison of two self-sampling modalities. *J Womens Health*. 2011;20(3):397-402.
75. Saidu R, Moodley J, Tergas A, Momberg M, Boa R, Wright T, et al. South African women's perspectives on self-sampling for cervical cancer screening: a mixed-methods study. *S Afr Med J*. 2018;109(1):47-52.
76. Dzuba IG, Díaz EY, Allen B, Leonard YF, Lazcano Ponce EC, Shah KV, et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. *J Womens Health Gen Based Med*. 2002;11(3):265-75.
77. Van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJ, Quint WG, Bekkers RL. Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. *J Clin Microbiol*. 2012;50(12):3937-43.
78. Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. Worldwide use of HPV self-sampling for cervical cancer screening. *Prev Med*. 2022;154:106900.
79. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. *Sex Transm Infect*. 2017;93(1):56-61.
80. Cho HW, Shim SR, Lee JK, Hong JH. Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis. *J Gynecol Oncol*. 2022;33(1):e4.
81. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. *Can J Public Health*. 2013;104(2):e159-66.
82. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). *Br J Cancer*. 2011;104(2):248-54.
83. Lam JU, Rebolj M, Møller Ejegod D, Pedersen H, Rygaard C, Lyng E, et al. Human papillomavirus self-sampling for screening nonattenders: opt-in pilot implementation with electronic communication platforms. *Int J Cancer*. 2017;140(10):2212-9.
84. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. *BMJ Glob Health*. 2019;4(3):e001351.
85. McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. *Sex Transm Infect*. 2006;82(2):169-74.
86. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. *BMJ*. 2018;363:k4823.
87. Klischke L, von Ehr J, Kohls F, Kampers J, Hülse F, Schmitz M, et al. Performance of a six-methylation-marker assay on self-collected cervical samples: a feasibility study. *J Virol Methods*. 2021;295:114219.
88. Daponte A, Michail G, Daponte AI, Daponte N, Valasoulis G. Urine HPV in the context of genital and cervical cancer screening: an update of current literature. *Cancers*. 2021;13(7):1640.
89. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. *Dis Markers*. 2007;23(4):315-30.
90. Cho HW, Hong JH, Lee JK. Detection of high-risk human papillomavirus infection and treatment of high-grade vaginal intraepithelial neoplasia: a single-institution study. *Int J Gynaecol Obstet*. 2021;154(2):227-32.
91. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health concern [homepage]. Geneva: WHO; 2020. Available from: <https://www.who.int/publications/item/9789240014107>

AUTHORS CONTRIBUTION

Conceptualization, MPP, ISS, and VF; methodology, MPP; software, MPP; validation, MPP, and MA; formal analysis, MPP, and ISS; data curation, MPP, and MA; writing – original draft, MPP, MA, and FVB; writing – review & editing, MPP, MA, LN, and ISS. All authors agree with the final version.

DECLARATION OF INTEREST STATEMENT

The authors report that there are no competing interests to declare.

FUNDINGS

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ENDEREÇO PARA CORRESPONDÊNCIA

Mafalda Paula-Pinto
E-mail: mafalda.paula.pinto@gmail.com
<https://orcid.org/0000-0003-0411-6601>

Recebido em 30-01-2024

Aceite para publicação em 28-12-2024



RESUMO

AUTOCOLHEITA VAGINAL *VERSUS* COLHEITA POR PROFISSIONAL DE SAÚDE PARA RASTREIO DO CANCRO DO COLO DO ÚTERO: UMA REVISÃO SISTEMÁTICA COM META-ANÁLISE DE PRECISÃO E ACEITABILIDADE

Introdução: Estratégias de autocolheita de DNA do papilomavírus humano (HPV) mostraram-se promissoras na detecção de doença; no entanto, não é clara a sua real potencialidade ou aceitabilidade pelas mulheres.

Objetivos: Como objetivo principal pretendeu-se determinar a precisão da detecção, estudo de não inferioridade, de HPV em amostras de autocolheita, comparativamente às colhidas por profissional de saúde. Secundariamente, pretendeu-se avaliar a aceitabilidade pelas mulheres.

Métodos: Realizou-se uma pesquisa sistemática maioritariamente em bases de dados eletrónicas (*MEDLINE*, *CENTRAL* e *Scopus*). Foram incluídos estudos que compararam os dois métodos de rastreio. A seleção dos estudos e extração de dados foi feita por dois autores de forma independente. Utilizou-se o *QUADAS2 Tool* e *Cochrane Risk of Bias Tool* para avaliar o risco de viés. A sensibilidade e a especificidade dos testes foram estimadas e elaboradas curvas SROC, utilizando o RevMan v. 5.4. e Meta-Disc para a análise de dados. Foi também realizada uma análise de subgrupo e de sensibilidade.

Resultados: Foram incluídos 67 artigos (precisão 47 e aceitabilidade 36) com uma amostra total de 18.615 mulheres, com idades entre 15-80 anos. Demonstrou-se uma sensibilidade de 86,4% e uma especificidade de 91,8%. Na análise de subgrupos não foram detetadas diferenças significativas relativas ao tipo de teste, dispositivo de autocolheita e respetivo transporte ou prevalência de HPV. Relativamente à aceitabilidade, as mulheres consideram a autocolheita fácil, confortável, privada e não constrangedora. 62,8% prefere a autocolheita.

Conclusão: Esta revisão sistemática e meta-análise demonstrou uma taxa de detecção de HPV não inferior à colheita por profissional de saúde e revelou ser um método com boa aceitabilidade pela maioria das mulheres. No entanto, ainda há poucas evidências sobre a sua viabilidade e aplicabilidade, pelo que futuramente a avaliação de custo-efetividade deste tipo de rastreio deve ser realizada a nível nacional e internacional.

Palavras-chave: Papilomavírus humano; Cancro do colo do útero; Autocolheita; Rastreio; Teste diagnóstico; Aceitabilidade.
